Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;4(1):33-8.
doi: 10.4103/0976-500X.107663.

Comparison of the efficacy and tolerability of ivabradine and ranolazine in patients of chronic stable angina pectoris

Affiliations

Comparison of the efficacy and tolerability of ivabradine and ranolazine in patients of chronic stable angina pectoris

Aditi Chaturvedi et al. J Pharmacol Pharmacother. 2013 Jan.

Abstract

Introduction: To compare the efficacy and tolerability of Ivabradine (IVA) and Ranolazine (RAN) in chronic angina patients.

Materials and methods: This was a follow-on, open-label trial conducted in a tertiary care hospital of Uttarakhand. Thirty patients each taking IVA 5 mg twice daily or RAN 500 mg twice daily were distributed to the respective groups. Patients were asked to fill a pretested questionnaire on frequency of anginal attacks and adverse reactions before and 2, 4 and 8 weeks after taking the respective medicines. Their blood pressure, heart rate and routine hematological and biochemical estimations were performed at baseline and after intervention. Results were statistically analyzed using different statistical tests, with P < 0.05 considered as significant.

Results: There was no significant difference in the frequency of anginal attacks per week between the groups. The adverse drug reactions (ADRs) reported in the IVA group were dizziness (30%), headache (16.6%), backache (16.6%), vertigo (13.3%), blurred vision (13.3%), muscle cramps (10%), arthralgia (10%), cough and dyspnea (6.6%), hypersensitivity rash (6.6%), fever (3.3%) and nausea (3.3%). The ADRs in the RAN group were nausea (26.6%), dizziness (23.3%), vomiting (3.3%), constipation (3.3%) and vertigo (3.3%). The blood pressure, heart rate and routine hematological and biochemical evaluations did not show any significant difference in the pre-post values. IVA significantly decreased the resting heart rate after eight weeks of intervention.

Conclusions: Both antianginal agents appeared equiactive. However, RAN had a better safety and tolerability profile than IVA. Serum sickness-like reaction was an adverse event noticed with IVA, which needs causality establishment.

Keywords: Antianginals; dizziness; equiefficacious; nausea; serum sickness-like reaction.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Consort flow chart of the efficacy and tolerability of Ivabradine and Ranolazine in patients of chronic stable angina pectoris

Similar articles

Cited by

References

    1. Murray CJL, Lopez AD. The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020.Cambridge, Harvard School of Public Health on behalf of the World Health Organization and The World Bank, 1996 (Global Burden of Disease and Injury Series, Vol. I)
    1. Gravel GM, Tardif JC. Ivabradine: The evidence of its therapeutic impact in angina. Core Evid. 2008;3:1–12. - PMC - PubMed
    1. McBride BF, White CM. Ranolazine: A novel metabolic modulator for the treatment of chronic stable angina. Formulary. 2003;38:461–4.
    1. Riccioni G. Ivabradine: From molecular basis to clinical effectiveness. Adv Ther. 2010;27:160–7. - PubMed
    1. Simon L, Ghaleh B, Puybasset L, Guidicelli JF, Berdeaux A. Coronary and haemodynamic effects of S16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659–66. - PubMed

LinkOut - more resources